ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2015
Question about Liu Y et al. entitled "Effect of c-erbB2 overexpression on prognosis in osteosarcoma: evidence from eight studies".
Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
- Comment on
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We read with great interest on the recent paper by Liu Y et al. "Effect of c-erbB2 overexpression on prognosis in osteosarcoma: evidence from eight studies" published online in Tumor Biology (Tumor Biol 5(9):8939-43, 2014). The investigators (Liu Y et al.) performed a meta-analysis to study the relationship between c-erbB2 expression and prognostic impact in patients with osteosarcoma. They conducted a comprehensive and detailed meta-analysis to reveal the prognostic role of c-erbB2 for osteosarcoma. As a result, eight studies with 411 osteosarcoma patients were involved to estimate the relationship. Positive expressions of c-erbB2 predicted poorer survival in osteosarcoma patients with the pooled RR of 1.53 (95 % CI 1.20-1.94, P = 0.0006). Finally, they concluded that c-erbB2 overexpression is related to poor prognostic of osteosarcoma and can be a useful clinical prognostic factor for those patients. Nevertheless, we have several queries which we would like to communicate with them.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.